# UNIFORM LIMITED OFFERING EXEMPTION

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

PURSUANT TO REGULATION D.

**SECTION 4(6) AND/OR** 

**HEC**EIVEI NOTICE OF SALE OF SECURITIES

OMB NUMBER: 3235-0076 Expires: May 31, 2005 Estimated average burden

ours per response..

SEC USE ONLY Seria Date Received

Name of Offering ( check if this is an amendment and name has changed, and indicate change.) Series B Preferred Stock Filing Under (Check box(es) that apply): □ Rule 504 □ ULOE □ Rule 505 X Rule 506 ☐ Section 4(6) Type of Filing: X New Filing ☐ Amendment A. BASIC IDENTIFICATION DATA 1. Enter the information requested about the issuer Name of Issuer ( Check if this is an amendment and name has changed, and indicate change.) Molecular Insight Pharmaceuticals, Inc. Address of Executive Offices (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code) 160 Second Street, Cambridge, MA 02142 (617) 492-5554 Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code) (if different from Executive Offices) See above See above Brief Description of Business MAR 18 2004 Research, development, marketing and distribution of molecular imaging agents. Type of Business Organization X corporation ☐ limited partnership, already formed □ other (please specify): □ business trust ☐ limited partnership, to be formed Month Actual or Estimated Date of Incorporation or Organization: X Actual Estimated Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: CN for Canada; FN for other foreign jurisdiction)

#### **GENERAL INSTRUCTIONS**

#### Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6)

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those state that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

#### ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1972 (6-02) 1 of 8

				B. INF	ORMATIC	ON ABOU	T OFFERI	NG				
											Yes	No
1. Has the is	suer sold, o	r does the i	ssuer intend	i to sell, to	non accredi	ited investo	rs in this of	fering?				X
			Ans	swer also in	Appendix,	Column 2,	if filing un	der ULOE.				
2. What is th	e minimun	n investmen	t that will b	e accepted	from any ir	ndividual?					\$25,000	0.00
21 11 11 10 11		, 0.0		- uccopica							Yes	No
3. Does the o	offering per	mit joint ov	vnership of	a single un	it?		•	•••••			X	
4. Enter the	informatio	n reguestes	l for each i	nercon who	hac haen	or will be:	naid or aiv	an directly	or indirect	lv anv o	ammiceia	n or simila
remuneration												
agent of a br persons to be												han five (5)
Full Name (L				ich a bioke	r or dealer,	you may se	t form the f	mormation	101 that blo	KEI OI GEZ	ner omy.	
· · · · · · · · · · · · · · · · · · ·	•	,	,									
Not Applicat Business or F		ddress (Nu	mber and S	treet City	State 7in (	Tode)						
Dusiness of r	costactice A	iddicss (ivu	moet and 5	ticet, city,	State, Zip C	zode)						
Not Applicab		. 5 1										
Name of Ass	ociated Bro	ker or Deal	er									
Not Applicab	le		<u>.</u>									
States in Whi		Listed Has S or check ind				hasers						All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
Full Name (L	<del>-</del>	<del></del>										<del></del>
		100, 11 1110711	,									
Business or R	esidence A	ddress (Nu	mher and S	treet City	State 7in (	ode)						
Dustriess of F	condence A	iddiess (14d	moer and B	ireci, City,	State, Zip C	Joue)						
Name of Asse	agisted Pro	kar or Deal	or .									
Name of Ass	ocialed bio	kei oi Dear	ei									
0	1.5	177 6	1 1 1 1	T . 1	C II I D	1						
States in Whi (Check ".		risted Has S										All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]_	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]
Full Name (L	ast name fi	rst, if indivi	dual)									
Business or R	tesidence A	ddress (Nu	mber and S	treet, City,	State, Zip C	Code)						
		·		•	•							
Name of Asso	ociated Bro	ker or Deale										
01 1.100												
States in Whi	oh Doron I	inted Har C	Coligitad a=	Intenda to 6	Soligit Dur-	hosars						
		r check ind								•••••	🗖	All States
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]

[VT]

[VA]

[WA]

[WV]

[WI]

[WY]

[PR]

[RI]

[SC]

[SD]

[TN]

[TX]

[UT]

#### A. BASIC IDENTIFICATION DATA

2. Enter the information requested for the following:

• Each promoter of the issuer, if the issuer has been organized within the past five years;

- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and

• Each general and managing partner of partnership issuers.

Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	X Executive Officer	X Director	☐ General and/or Managing Partner
Full Name (Last name first, if inc	dividual)				
Babich, John D.					
Business or Residence Address	(Numb	er and Street, City, State, 2	Lip Code)		
160 Second Street, Cambridge, M	1A 02142				
Check Box(es) that Apply:	☐ Promoter	X Beneficial Owner	X Executive Officer	X Director	General and/or
Full Name (Last name first, if ind	lividual)				Managing Partner
Barlow, David S.					
Business or Residence Address	(Numb	er and Street, City, State, 2	Cip Code)		
160 Second Street, Cambridge, M	1A 02142				
Check Box(es) that Apply:	☐ Promoter	X Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or
Full Name (Last name first, if ind	lividual)				Managing Partner
Elmahleh, David	,				
Business or Residence Address	(Numb	er and Street, City, State, Z	(ip Code)		
29 Hartman Dood Nauston MA			. ,		
38 Hartman Road, Newton, MA Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	X Director	☐ General and/or
Pull No. (C. ) (C. )	P. C. D.				Managing Partner
Full Name (Last name first, if ind	iividuai)				
Greenfield, Keith					
Business or Residence Address	(Numb	er and Street, City, State, Z	(ip Code)		
12 Cedar Hill Road, Dover, MA	02030				
Check Box(es) that Apply:	☐ Promoter	X Beneficial Owner	☐ Executive Officer	X Director	☐ General and/or Managing Partner
Full Name (Last name first, if ind	lividual)		<del> </del>		
Poitras, James					
Business or Residence Address	(Numbe	er and Street, City, State, Z	ip Code)	·	
198 Highland Street, Holliston, M	1A 01746				
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	X Director	☐ General and/or
					Managing Partner
Eckelman, William					
Full Name (Last name first, if ind	ividual)				
10432 Snow Point Drive, Betheso	la, MD 20814				
Business or Residence Address	(Numbe	er and Street, City, State, Z	ip Code)		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	X Executive Officer	X Director	☐ General and/or Managing Partner
Full Name (Last name first, if ind McCray, John	ividual)				
Business or Residence Address	(Numbe	er and Street, City, State, Z	ip Code)		<del></del>
160 Second Street, Cambridge, M	IA 02142				

# C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box   and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.		
	Type of Security	Aggregate Offering Price	Amount Already e Sold
	Debt	\$_0	<u> </u>
	Equity	\$ 8,052000	\$_5,650,160
	□ Common X Preferred		
	Convertible Securities (including warrants)	\$ 8 <u>,</u> 052 <u>,0</u> 00	\$ <u>5,650,16</u> 0
	Partnership Interests		
	Other (Specify)	\$	
		\$	
	Total	\$ <u>8,052,000</u>	\$ <u>5,650,160</u>
2.	Answer also in Appendix, Column 3, if filing under ULOE.  Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number Investors	Aggregate Dollar Amou of Purchases
	Accredited Investors	_6	\$ <u>5,650,160</u>
	Non-accredited Investors	_ 0	\$ <u>0</u>
	Total (for filings under Rule 504 only)		. \$
	Answer also in Appendix, Column 4, if filing under ULOE.		. Ψ
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
	Type of offering	Type of Security	Dollar Amour Sold
	Rule 505		
	Regulation A		\$
	Rule 504		\$
-	Total		s
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		<u>     \$_0</u>
	Printing and Engraving Costs		<u> </u>
	Legal Fees		\$20,000 (est.)
	Accounting Fees		□ \$ <u>0</u>
	Engineering Fees		□ \$ <u>0</u>
	Sales Commissions (specify finders' fees separately)		□ \$ <u>0</u>
	Other Expenses (identify)		□ \$ 0
	Total		□ \$20,000(est.)

C. OFFERING PRIC	CE, NUMBER OF INVESTORS, EXPENSES AND U	SE OF P	ROCEEDS		
1 and total expenses furnished in respon "adjusted gross proceeds to the issuer."      5. Indicate below the amount of the adjusted used for each of the purposes shown. If the estimate and check the box to the left of the stimate and check the box to the left of the stimate and check the stimate and ch	gate offering price given in response to Part C - Question ase to Part C - Question 4.a. This difference is the gross proceeds to the issuer used or proposed to be a amount for any purpose is not known, furnish an e estimate. The total of the payments listed must equal at forth in response to Part C - Question 4.b above.				\$ <u>8,032,000</u>
, g o p	(		Payments to Officers, Directors, & Affiliates	;	Payments To Others
Salaries and fees		. 🗆	\$		\$
Purchase of real estate		. 🗆	\$		\$
Purchase, rental or leasing and installa	tion of machinery and equipment	🗆	\$		\$
Construction or leasing of plant building	ngs and facilities	🗆	\$		\$
offering that may be used in exchange	ling the value of securities involved in this for the assets or securities of another		\$		\$ <u>·</u>
Repayment of indebtedness			\$		\$
Working Capital			\$		
Other (specify):		_ 🗆	\$		\$
•			\$		\$
			\$		
Total Payments Listed (Column totals	added)		X \$ <u>8</u>	<u>,032,</u>	000
	D. FEDERAL SIGNATURE				
following signature constitutes an undertak	e signed by the undersigned duly authorized person. king by the issuer to furnish to the U.S. Securities and E e issuer to any non-accredited investor pursuant to parag	xchange	Commission, u		
(ssuer (Print or Type)	Signature		Date March //, 2	004	
Molecular Insight Pharmaceuticals, Inc. //k/a Biostream, Inc.	Del Mal				
Name of Signer (Print or Type)	Title of Signer (Print or Type)				
David S. Barlow	Chief Executive Officer				
	<u></u>		·		<del></del>

----- ATTENTION -----

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

E. STATE SIGNATURE		
Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?	Yes □	No X
See Appendix, Column 5, for state response.		

- 2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239,500) at such times as required by state law.
- 3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
- 4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type) Molecular Insight Pharmaceutical, Inc. f/k/a Biostream, Inc.	Signature Del I Bail	Date March <u>//</u> , 2004
Name of Signer (Print or Type)	Title of Signer (Print or Type)	
David S. Barlow	Chief Executive Officer	

#### Instruction

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

# APPENDIX

Γ 1		2	3						5
	Inten to non-	d to sell accredited rs in State 3-Item 1)	ell Type of dited security Type of investor and state amount purchased in State			Disqua under St (if yes explan waiver	Jification ate ULOE s, attach ation of granted) -Item 1)		
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL									
AK									
AZ			-						
AR									
CA		X	Series B Preferred Stock \$25,000	1	\$25,000	0	0		X
СО									
СТ		X	Series B Preferred Stock \$600,000	2	\$600,000	0	0		X
DE			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,						
DC									
FL									
GA									
HI									
ID									
IL		· · · · · · · · · · · · · · · · · · ·							
IN									
IA									
KS									
KY									
LA									
ME					<del></del>	· ·			
MD							<u> </u>		
MA									
MI									
MN							L		

# APPENDIX

1		2	3			4		Disqua	5 lification ate ULOE
	to non-	d to sell accredited rs in State 3-Item 1)	Type of security and aggregate offering price offered in state (Part C Item 1)		Type of investor and amount purchased in State (Part C-Item 2)		(if yes, attach explanation of waiver granted) (Part E-Item 1)		
				Number of Accredited	·	Number of Non-Accredited			
State	Yes	No_		Investors	Amount	Investors	Amount	Yes	No
MS									
МО		Х	Series B Preferred Stock	1	\$25,000	0	0		X
			\$25,000						
MT									
NE									
NV									
NH									
NJ									
NM	_	_							
NY									
NC									
ND									
ОН									
ок									
OR									
PA									
RI									
SC									
SD									
TN									
TX									
UT									
VT									
VA	i								
WA									
wv									
WI									
WY									

ļ	PR						
	793114v	/1			*		

# FORM U-2 UNIFORM CONSENT TO SERVICE OF PROCESS

### KNOW ALL MEN BY THESE PRESENTS:

That the undersigned, Molecular Insight Pharmaceuticals, Inc. f/k/a Biostream, Inc. a corporation organized under the laws of the Commonwealth of Massachusetts, for purposes of complying with the laws of the states indicated hereunder relating to (i) either the registration or sale of securities or (ii) the furnishing of investment advisory services, hereby irrevocably appoints the officers of the states so designated hereunder and their successors in such offices, its attorney in those states so designated upon whom may be served any notice, process or pleading in any action or proceeding against it arising out of, or in connection with, the sale of securities or out of violation of the aforesaid laws of the states so designated; and the undersigned does hereby consent that any such action or proceeding against it may be commenced in any court of competent jurisdiction and proper venue within the states so designated hereunder by service of process upon the officers so designated with the same effect as if the undersigned was organized or created under the laws of that state and have been served lawfully with process in that state.

It is requested that a copy of any notice, process or pleading served hereunder be mailed to:

Molecular Insight Pharmaceuticals, Inc. 160 Second Street Cambridge, MA 02142 Attn: President

Place an "X" before the names of all states for which the person executing this form is appointing the designated Officer of that state as its attorney in that state for receipt of service of process:

	ALABAMA	Secretary of State.	ILLINOIS	Secretary of State.
	ALASKA	Administrator of the	INDIANA	Secretary of State.
		Division of Banking and Corporations, Department of Commerce and Economic	IOWA	Commissioner of Insurance.
		Development.	KANSAS	Secretary of State.
	ARIZONA	The Corporation Commission.	KENTUCKY	Director, Division of Securities.
	ARKANSAS	The Securities Commissioner.	LOUISIANA	Commissioner of Securities.
X	CALIFORNIA	Commissioner of Corporations.	MAINE	Administrator, Securities Division.
	COLORADO	Securities Commissioner.	MARYLAND	Commissioner of Securities.
Х	CONNECTICUT	Banking Commissioner.	MASSACHUSETTS	Secretary of State.
	DELAWARE	Securities Commissioner.	MICHIGAN	Administrator, Corporation and Securities Bureau,
	DISTRICT OF COLUMBIA	Public Service Commission.		Department of Commerce.
		Donato and af Paulina	MINNESOTA	Commissioner of Commerce.
	FLORIDA	Department of Banking and Finance.	MISSISSIPPI	Secretary of State.
	GEORGIA	Commissioner of Securities.	X MISSOURI	Securities Commissioner.
· · · · · · · · · · · · · · · · · · ·	GUAM	Administrator, Department of Finance.	MONTANA	State Auditor and Commissioner of Insurance.
	HAWAII	Commissioner of Securities & Consumer Affairs.	NEBRASKA	Director of Banking and Finance.
	IDAHŌ	Director, Department of Finance.	NEVADA	Secretary of State.

NEW HAMPSHIRE	Secretary of State.	SOUTH CAROLINA	Office of Attorney General.
NEW JERSEY	Chief, Securities Bureau.	SOUTH DAKOTA	Director of the Division of Securities.
NEW MEXICO	Director of Securities.	TENNESSEE	Commissioner of Commerce and Insurance.
NEW YORK	Secretary of State.	TEVAC	
NORTH CAROLINA	Secretary of State.	TEXAS	Securities Commissioner.
NORTH DAKOTA	Securities Commissioner.	UTAH	Director, Division of Securities.
OHIO	Secretary of State.	VERMONT	Commissioner of Banking, Insurance, Securities, and Health Care Administration
OREGON	Director, Department of Insurance and Finance.	VIRGINIA	Clerk, State Corporation Commission.
OKLAHOMA	Department of Securities.	WASHINGTON	Director of the Department
PENNSYLVANIA	Pennsylvania does not require filing of a Consent	Wishintoron	of Licensing.
	to Service of Process.	WEST VIRGINIA	Commissioner of Securities.
PUERTO RICO	Commissioner of Financial Institutions.	WISCONSIN	Department of Financial Institutions, Division of Securities
RHODE ISLAND	Director of Business Regulation.	WYOMING	Secretary of State.
Dated this 11 day of MAC	<u>L <b>h</b></u> , 2004	<u>APPLICANT</u>	
		Molecular Insight Pharmaceutica f/k/a Biostream, Inc.	als, Inc.
(CORPORATE SEAL)		By: David S. Barlow Chief Executive Officer	sal
THE STATE OF Mass COUNTY OF Worfolk	\$ \$ \$		
On this <u>I</u> day of <u>Mar</u> Dave Borlow, known personal	by 2004, before me, flu ly to me to be the ED to do, executed the foregoi	of the above named Coufaing instrument for the purposes the	d officer, personally appeared and acknowledged that he, rein contained, by signing the
IN WITNESS WHERE	OF, I have hereunto set my l	hand and official seal.	
. 74 to 15 t		Mude Julia Notary Public Commissioner of	
(SEAL)	· .	· · · · · · · · · · · · · · · · · · ·	// -

BO:104716v1